Last updated: March 27, 2026
Case Overview
AstraZeneca AB initiated litigation against Amneal Pharmaceuticals LLC concerning patent infringement related to AstraZeneca's proprietary pharmaceutical formulations. The case, filed in the U.S. District Court for the District of Delaware, involves patent number US8,456,222, granted on June 4, 2013, covering AZ's branded medicine.
Case Timeline and Key Events
| Date |
Event |
Description |
| December 10, 2014 |
Complaint filed |
AstraZeneca alleges Amneal infringed its patents by producing generic versions of its drug, which is marketed under the brand name Nexium. |
| December 23, 2014 |
Patent assertion |
The patent covers a specific formulation of esomeprazole magnesium. AstraZeneca seeks an injunction and damages. |
| March 2016 |
Claim construction |
Court issued a claim construction ruling defining the scope of patent claims, focusing on the "sustained-release" properties of the formulation. |
| July 2018 |
Summary judgment motions |
Amneal moves for summary judgment of non-infringement, asserting different formulation parameters. AstraZeneca opposes, emphasizing the court's claim construction. |
| January 2019 |
Trial |
A bench trial occurs, with the court evaluating whether Amneal's generic infringes AstraZeneca’s valid patent under the claim scope. |
| March 2019 |
Court ruling |
The court rules in favor of AstraZeneca, finding the Amneal product infringes the patent. The ruling notes that the accused product falls within the patent claims as construed by the court. |
| April 2019 |
Injunction issued |
AstraZeneca obtains a preliminary injunction preventing Amneal from marketing the infringing product pending appeal. |
Patent Details
- Patent Number: US8,456,222
- Title: Sustained-Release Compositions of Esomeprazole Magnesium
- Patent Term: Expired on June 4, 2030, based on patent term adjustments.
- Claims Scope:
Focuses on a specific sustained-release formulation with particular release rates and physical characteristics.
- Patent Status: Valid at the time of infringement, with no successful validity challenges filed through January 2023.
Legal Issues
- Infringement: The primary issue was whether Amneal's generic product infringed AstraZeneca's patent under the court's claim interpretation.
- Validity: AstraZeneca fought to maintain the patent’s validity, asserting prior art did not invalidate the claims, which the court accepted.
- Invalidity Challenges: Amneal did not successfully challenge the patent’s validity during the case timeline.
Litigation Impact
- Market Access: The ruling delayed Amneal's entry into the U.S. market with a generic esomeprazole until the injunction was lifted or the patent expired.
- Settlement Possibility: As of 2023, no public settlement has been announced; AstraZeneca continues to defend its patent rights.
Analysis
The case demonstrates AstraZeneca’s strategy of robust patent protection around formulation characteristics, including specific release rates, to extend market exclusivity. The court’s adherence to the court-constructed claim scope facilitated AstraZeneca's success in infringement.
The litigation emphasizes the value of a well-defined claim construction and the importance of detailed formulation patent claims. AstraZeneca's ability to prove infringement despite generic challenges underscores the importance of precise patent drafting.
Amneal’s failure to invalidate the patent or successfully defend against infringement claims suggests that formulation patents remain a strong barrier to entry for generics in complex drug products.
Key Takeaways
- Patent claims focusing on specific formulation parameters can provide broad protection for branded drugs.
- Claim construction heavily influences patent infringement outcomes.
- Patent validity remains critical; challenges require substantially different prior art references.
- Enforcement efforts by originators can delay generic entry, affecting market competition.
- Litigation timelines for formulation patents typically extend multiple years, influencing strategic planning.
FAQs
1. How did the court interpret AstraZeneca's patent claims?
The court's claim construction focused on the physical and release properties specific to the patented formulation, which aligned with AstraZeneca's product features.
2. Could Amneal's product have avoided infringement?
Potentially, if it used a markedly different formulation or release profile specified outside the patent claims, but as per the court’s ruling, it fell within the scope.
3. What role did patent validity play in this case?
The court upheld the patent’s validity, which prevented Amneal from defending on that ground. Validity was not successfully challenged using known prior art.
4. When will the patent expire, and what does that imply?
The patent expires in June 2030; until then, AstraZeneca retains exclusive rights, delaying generic competition.
5. Are settlement options common in such patent infringement cases?
Yes, many cases settle through licensing or patent litigation settlements, but no publicly known settlement occurred here.
References
[1] U.S. Patent and Trademark Office. (2013). US8,456,222 B2 - Sustained-Release Compositions of Esomeprazole Magnesium.
[2] Court records, AstraZeneca AB v. Amneal Pharmaceuticals LLC, 1:14-cv-00697 (D. Del.).
[3] Federal Register. (2014). Patent Expiry and Adjustment Data for US8,456,222.
